Latest Articles

Publication Date
TMEM119 Links to Ovarian Endometriosis Progression via MAPK-Mediated Suppression of Ectopic Endometrial Stromal Cell Senescence.

Transmembrane protein TMEM119 has been implicated in tumor progression (e.g., ovarian cancer), but its role and underlying mechanism in ovarian endometriosis (EM) remain elusive. Thus, this study aimed to investigate …

Published: Feb. 19, 2026, midnight
Drospirenone promotes apoptosis in ectopic but inhibits proliferation in eutopic human endometrial stromal cells.

Endometriosis is a complex gynecological condition characterized by endometrial tissue growing outside the uterus. In many in vitro studies, almost all progestins have indicated the anti-proliferation and apoptosis of endometriotic …

Published: Jan. 30, 2026, midnight
Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.

To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.

Published: Dec. 8, 2025, midnight
Estetrol drospirenone effective as firstline endometriosis treatment: Study - Medical Dialogues

Estetrol drospirenone effective as firstline endometriosis treatment: Study Medical Dialogues

Published: Dec. 6, 2024, 1:30 p.m.
Comparative study on the effects of combined oral contraceptives and dienogest in women with endometriosis‑associated chronic pelvic pain.

To compare the effects of five combined oral contraceptives (COCs) - ethinylestradiol (EE) 30 μg/dienogest (DNG) 2 mg, EE 20 μg/drospirenone (DRSP) 3 mg, 17β-estradiol (E2) 1.5 mg/nomegestrol acetate (NomAc) …

Published: Nov. 13, 2024, midnight
Efficacy and safety of estetrol (15 mg)/drospirenone (3 mg) combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: a multicenter, placebo-controlled, double-blind, randomized study.

To evaluate the efficacy and safety of the estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) combination in a cyclic regimen in Japanese women with primary and secondary dysmenorrhea.

Published: Nov. 8, 2024, midnight
Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study.

Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective …

Published: Oct. 13, 2024, 4:35 p.m.
Use of Continuous Oral Drospirenone for Menstrual Suppression in Adolescents.

To describe experiences of adolescents taking continuous drospirenone (DRSP-C) oral contraceptives, without placebo, for menstrual suppression, including breakthrough bleeding and other side-effects.

Published: Oct. 10, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!